Last reviewed · How we verify
AZD3241
AZD3241 is a small molecule inhibitor of the PI3K delta and PI3K gamma enzymes.
AZD3241 is a small molecule inhibitor of the PI3K delta and PI3K gamma enzymes. Used for Relapsed or refractory chronic lymphocytic leukemia (CLL).
At a glance
| Generic name | AZD3241 |
|---|---|
| Also known as | AZD3241 to match placebo administered for 12 weeks. |
| Sponsor | AstraZeneca |
| Drug class | PI3K inhibitor |
| Target | PI3K delta and PI3K gamma |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
By inhibiting these enzymes, AZD3241 reduces the activity of the PI3K/AKT signaling pathway, which is involved in the proliferation and survival of cancer cells. This leads to the induction of apoptosis and inhibition of tumor growth.
Approved indications
- Relapsed or refractory chronic lymphocytic leukemia (CLL)
Common side effects
- Neutropenia
- Thrombocytopenia
- Anemia
Key clinical trials
- AZD3241 PET MSA Trial, Phase 2, Randomized,12 Week Safety and Tolerability Trial With PET in MSA Patients (PHASE2)
- A Study to Assess Safety and Tolerability of Oral AZD3241 in Patients With Parkinson's Disease (PHASE2)
- PET Study in Parkinson's Disease Patients (PHASE2)
- To Assess the Effect of Administration of 2 Formulation of AZD3241 on Blood Concentration in Healthy Volunteers (PHASE1)
- Study to Evaluate Different Extended Release (ER)-Formulations and Multiple Ascending Dosing of AZD3241 (PHASE1)
- Investigating Safety, Tolerability and Pharmakinetics When Giving Single and Fractionated Doses of AZD3241 to Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AZD3241 CI brief — competitive landscape report
- AZD3241 updates RSS · CI watch RSS
- AstraZeneca portfolio CI